

Form PTO/SB/08 INFORMATION DISCLOSURE CITATION OF A PENDING APPLICATION (Use several sheets if necessary)	Docket Number (Optional) SEPR-P01-051	Application Number 10/087,596
Applicant Currie et al.		Group Art Unit 1614
Filing Date March 1, 2002		

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PS	AD	4,314,081	2/2/82	Molloy et al.	564	347
PS	AE	4,338,317	7/6/82	Temple, Jr. et al.	424	250
PS	AF	4,626,549	12/2/86	Molloy et al.	514	359
PS	AG	5,116,852	5/26/92	Gammans	514	649
PS	AH	5,708,035	1/13/98	Young et al.	514	252
PS	AI	6,034,085	3/7/00	Joshi et al.	514	252

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
PS	AJ	WO 00/61128	10/19/00	PCT			


OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

PS	AK	Fava, M. New Approaches to the Treatment of Refractory Depression. <i>J. Clin. Psychiatry</i> 61, (suppl 1) 26-32 (2000).
PS	AL	Khouzam, H.R. The Antidepressant Nefazodone: A Review of Its Pharmacology, Clinical Efficacy, Adverse Effects, Dosage, and Administration. <i>J. Psychosocial Nursing</i> 38, 20-25 (August 2000)..
PS	AM	Nemeroff, C.B. et al. Newer Antidepressants and the Cytochrome P450 System. <i>Am. J. Psychiatry</i> 153, 311-320 (March 1996).
PS	AN	Robinson, D.S. et al. Therapeutic Dose Range of Nefazodone in the Treatment of Major Depression. <i>J. Clin. Psychiatry</i> 57 (suppl 2) 6-9 (1995).
PS	AO	Sanchez, C. & Hyttel, J. Comparison of the Effects of Antidepressants and Their Metabolites on Reuptake of Biogenic Amines and on Receptor Binding. <i>Cellular and Molecular Neurobiology</i> 19, 467-489 (1999).
PS	AP	van Laar, M.W. Nefazodone: Psychomotor and Cognitive Effects. <i>Drugs</i> 54, 186-187 (July 1997).

EXAMINER <i>Phyllis Spivack</i>	DATE CONSIDERED <i>10/12/03</i>
------------------------------------	------------------------------------

EXAMINER: Initial if citation considered whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



Approved for use through 10/31/2002 OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) #1				Complete if Known	
				Application Number	10/087596
				Filing Date	March 1, 2002
				First Named Inventor	Mark G. Currie
				Art Unit	1614
Examiner Name	Spilack				
Sheet	1	of	2	Attorney Docket Number	SEPR-P01-051

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
PS	AQ	4,131,675	12-26-1978	Silvestrini	


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
PS	AR	EP 0 966 966	12-29-1999	Squibb Bristol Myers Co.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
PS	AS	Davidson, G. "Mixing SSRIs" from Dr. Bob's Psychopharmacology Tips (11 May 1996). Retrieved from http://www.dr-bob.org/tips/split/mixing-antidepressants.html (28 Nov. 2002).			
PS	AT	Fontaine, R. et al. A Double-Blind Comparison of Nefazodone, Imipramine, and Placebo in Major Depression. J. Clin. Psych. 55, 234-241 (1 June 1994).			
PS	AU	Maes, M. et al. Efficacy of Treatment with Trazodone in Combination with Pindolol or Fluoxetine in Major Depression. J. Affective Disorders 41, 201-210 (16 Dec. 1996).			
PS	AV	Majeroni, B.A. et al. The pharmacologic treatment of depression. J. Am. Board Family Practice 11(2), 127-139 (March 1998).			
PS	AW	Nierenberg, A.A. et al. Possible Trazodone Potentiation of Fluoxetine: A Case Series. J. Clin. Psych. 53, 83-85 (March 1992).			
PS	AX	Raffa, R.B. et al. Etoperidone, Trazodone and MCPP: In Vitro and In Vivo Identification of Serotonin 5-HT1A (Antagonistic) Activity. Psychopharmacol. 108, 320-326 (1992).			
PS	AY	Trivedi, M.H. et al. Algorithm for the Treatment of Chronic Depression. J. Clin. Psych. 62 Suppl. 6, 22-29 (2001).			
PS	AZ	Vol Moltke, L.L. et al. Meta-chloro-phenylpiperazine (mCPP) P450-3A-dependent clearance. Clin. Pharmacol. Therapeutics 65, 144 (Feb. 1999).			

Examiner Signature	Phyllis Spilack	Date Considered	10/13/03
-----------------------	-----------------	--------------------	----------




PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/087596
				Filing Date	March 1, 2002
				First Named Inventor	Mark G. Currie
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	SEPR-P01-051

	BA	Zajacka, J.M. et al. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J. Clin. Psych. 56, 338-343 (Aug. 1995).	
---	----	---	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	10/12/03
-----------------------	---	--------------------	----------

Form PTO/SB/08

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number (Optional)

SEPR-P01-051

Applicant

Currie et al.

Filing Date


March 1, 2002

Application Number

10/087,596

Group Art Unit

1614

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED

SEP 13 2002

FOREIGN PATENT DOCUMENTS

TECH CENTER 1600/2900

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
					YES	NO

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

PS	AA	Benazzi, F. Dangerous interaction with nefazodone added to fluoxetine, desipramine, venlafaxine, valproate and clonazepam combination therapy. <i>J Psychopharmacol.</i> 11, 190-1 (1997).
PS	AB	MHi Ask the Expert – SSRIs and Nefazodone. http://www.mhsource.com/expert/exp1090996p.html , (Sept., 1996).
PS	AC	Smith, D.L. & Wenegrat, B.G. A Case Report of Serotonin Syndrome Associated with Combined Nefazodone and Fluoxetine. <i>J. Clin. Psychiatry</i> 61, 146 (Feb. 2000).

EXAMINER

Phyllis Spinack

DATE CONSIDERED

10/12/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

COPY OF PAPERS
ORIGINALLY FILED